All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.

2020-08-04T16:00:18.000Z

Phase II study of tisagenlecleucel in patients with R/R FL meets its primary endpoint

Aug 4, 2020
Share:

Bookmark this article

On August 4, 2020, positive results were announced from the phase II ELARA trial (NCT03568461), investigating tisagenlecleucel in patients with relapsed or refractory (R/R) follicular lymphoma (FL).

Tisagenlecleucel is an anti‐CD19 chimeric antigen receptor T (CAR T) cell, currently approved for the treatment of pediatric and young adult patients (up to 25 years of age) with R/R acute lymphoblastic leukemia, and adult patients with R/R  diffuse large B-cell lymphoma. In April, tisagenlecleucel received U.S. Food and Drug Administration (FDA) regenerative medicine advanced therapy designation for the treatment of patients with R/R FL, based on preliminary results from the ELARA trial.

The ELARA trial is a single-arm, multicenter, open-label trial investigating the efficacy and safety of tisagenlecleucel in adult patients with R/R FL. At the interim analysis, the study met the primary endpoint of complete response rate, with no new safety signals observed.

Severe side effects associated with tisagenlecleucel included cytokine release syndrome (CRS) and neurological toxicities. Due to the risk of CRS and neurologic toxicities, tisagenlecleucel is only available through a restricted program under a risk evaluation and mitigation strategy.

Results from the ELARA trial will be included in US and EU regulatory submissions.

  1. Novartis. Novartis announces Kymriah® meets primary endpoint at interim analysis of pivotal study in follicular lymphoma. https://www.novartis.com/news/media-releases/novartis-announces-kymriah-meets-primary-endpoint-interim-analysis-pivotal-study-follicular-lymphoma. Published Aug 4, 2020. Accessed Aug 4, 2020.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

HCPs, what is your preferred format for educational content on the Lymphoma Hub?
60 votes - 48 days left ...

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox